OTC Watch

All stocks / NWBO

NORTHWEST BIOTHERAPEUTICS INC NWBO

Northwest Biotherapeutics (NWBO): convertible notes mentioned in an 8-K in July 2026, a late 10-K notice in March 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated floatCostly financingLate filing OTCQBMaryland, USA
Live quote on OTC Markets

Market listing

Full name
NORTHWEST BIOTHERAPEUTICS INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Website
www.nwbio.com/
Source: Stockwatch, 2026-11-17

News headlines

Northwest Biotherapeutics Announces Expansion of Its Technical Team
2026-10-26 11:16 · News Release
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax(TM)-L Production
2026-10-08 16:53 · News Release
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference
2026-10-06 03:00 · News Release
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
2026-08-06 11:58 · News Release
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax(TM)-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
2026-07-08 14:24 · News Release
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
2026-07-02 14:17 · News Release
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
2026-06-01 08:30 · News Release
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
2026-05-11 08:30 · News Release
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
2026-04-30 12:30 · News Release
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
2026-04-21 09:30 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$1,378,000
Net loss
($60,162,000)
What it means

It spends more than it earns

Under strain

Customers paid it $1.4 million in the year. It lost $60.2 million. For every $1 that came in, about $44.66 went out.

The report says
Cash and cash equivalents
$3,040,000
Net cash used in operating activities
($44,763,000)
What it means

The cash could run out soon

Under strain

It had $3 million in the bank and used about $3.7 million a month. At that pace the money lasts less than a month unless it borrows or sells more shares.

The report says
Total assets
$81,290,000
Total liabilities
$128,860,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $81.3 million. Its debts and unpaid bills add up to $128.9 million. That is about $1.59 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-10

Estimated float about 1,811,970,770 shares as of 2026-11-10: 1,811,970,770 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-07-31

8-K filed 2026-07-31 mentions: convertible note, equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Late filing2026-03-31

Filed NT 10-K on 2026-03-31: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Costly financing2025-11-20

8-K filed 2025-11-20 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-11-13
1.54B
2025-12-31
1.56B
2026-03-31
1.61B
2026-05-13
1.64B
2026-06-30
1.67B
2026-08-13
1.71B
2026-09-30
1.76B
2026-11-10
1.81B

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-13 10-Q10-Q
2026-10-30 8-KFORM 8-K
2026-08-14 10-Q10-Q
2026-07-31 424B5424B5
2026-07-31 8-KFORM 8-K
2026-07-20 8-KFORM 8-K
2026-05-15 10-Q10-Q
2026-04-20 EFFECT
2026-04-16 POS AMPOS AM
2026-04-15 10-K10-K
2026-04-07 8-KFORM 8-K
2026-03-31 NT 10-KNT 10-K

Common questions about NWBO

Does NWBO file reports with the SEC?

Yes. Northwest Biotherapeutics files with the SEC under company number 0001072379. The most recent filing we hold is a 10-Q dated 2026-11-13.

Source record

How many NWBO shares are outstanding?

1,811,970,770 shares as of 2026-11-10, as reported to the SEC.

Source record

Has NWBO filed reports late?

Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-K on 2026-03-31. A notice means a report was not ready on time; check whether the report followed.

Source record

Is Northwest Biotherapeutics making money?

Customers paid it $1.4 million in the year. It lost $60.2 million. For every $1 that came in, about $44.66 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record